10:22 AM
 | 
Apr 19, 2019
 |  BC Week In Review  |  Company News  |  Regulatory

FDA approves Ibrance for men with breast cancer

Pfizer said FDA approved an sNDA for Ibrance palbociclib based on real-world data to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer...

Read the full 91 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review